With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Global workforce inequities are widening the cancer survival gap. Prof David Kerr highlights the stark realities and calls for an improved training approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results